Podcasts about oncologists

Cancer, Character, and Calling: The Oncologist's Journey, hosted by Girindra Raval, MD, is a podcast highlighting how top oncologists have navigated the field over the course of their careers, the passion that drove them to enter the oncology space, and the ongoing work that will continue to transform cancer care. Each episode, Raval will sit down with a top oncologist to dive into their background, highlight their career achievements, discuss key issues still being addressed in their field, and explore their interests outside of the clinic and lab.In this episode, Raval welcomed Hossein Borghaei, DO, MS, who is the chief of the Division of Thoracic Medical Oncology, the codirector of the Immune Monitoring Facility, the Gloria and Edmund M. Dunn Chair in Thoracic Oncology, and a professor in the Department of Hematology/Oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. Their conversation focused on Borghaei's personal journey into medicine and oncology, highlighting how immigration, mentorship, and scientific curiosity shaped his career and philosophy of patient care.Reflecting on his career, Borghaei described major advances in the field of lung cancer treatment, including targeted therapies and immunotherapy, which he witnessed firsthand. He emphasized that clinical observation and collaboration have driven progress in this area of oncology and will continue to do so. He believes immunotherapy still holds untapped potential and that future breakthroughs will come through continued scientific cooperation.Borghaei advised trainees to persist throughout their careers despite rejection, seek mentorship, and remain committed to improvement. He views artificial intelligence as a powerful tool for research and diagnostics but not a replacement for physicians, emphasizing the irreplaceable value of human connection in patient care. Throughout the interview, he stressed optimism, compassion, and lifelong learning as essential qualities for oncologists, highlighting the profound relationships formed with patients even in the most difficult moments.

New treatment options for melanoma are being described as the global gold standard. Pharmac's proposing to increase access to nivolumab and ipilimumab for treating stage 3b and 4 melanoma, from May. Pre-surgery use of the immunotherapy drugs can lower the chance of cancer returning. Medical oncologist Dr Gareth Rivalland told Ryan Bridge it's state of the art treatment. He says it's the best combination and will kill off the cancer in 60% of people. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Valentine's Day is right around the corner, and love is in the air! If there's one thing most people love, it's receiving a great job offer. Even better is when you get more than one. But job offers aren't always as simple as picking the best salary; you have to look at the whole compensation plan, including retirement benefits. Nate Reineke and Chelsea Jones break down the math that could help you decide if a higher salary and a 401K are a better choice than a pension plan. We'll discuss some non-financial elements that could also factor into the decision, like how leaving the job could leave you without the pension anyway. We also answer your colleagues' questions. A Surgeon and an Oncologist in Oregon both ask, “I want to set aside money for my kids, should I use a Trump account?” An ENT in Florida wonders, “When can I buy a boat?” A Private Practice Sports Medicine Physician in Wisconsin says, “Can I use a 529 account to pay for CME that I would like to attend and can deduct pretax?” Are you ready to turn worries about taxes and investing into all the money you need for college and retirement? It's time to make a plan and get on track. To find out if we're a match visit physicianfamily.com and click get started or, you can ask a question of your own by emailing podcast@physicianfamily.com. See marketing disclosures at physicianfamily.com/disclosures

Dr. Evan Noch interviews Dr. Lisa DeAngelis about her career in neuro-oncology, role as Chair of Neurology and Physician-in-Chief at Memorial Sloan Kettering Cancer Center, and advice for trainees entering the field.

In this episode, I'm joined by Dr Amy Comander, an expert I've been wanting to bring onto the podcast for a long time.Amy is a breast oncologist, lifestyle medicine physician, and Menopause Society Certified Practitioner based at Massachusetts General Hospital. She is, quite honestly, many people's dream oncologist — someone who truly understands that surviving cancer is about far more than getting through treatment.In this conversation, we start with menopause and ask an important question: what drove a breast oncologist to skill up so deeply in menopause and lifestyle medicine?We explore lifestyle medicine through a menopause-after-cancer lens, discussing what is genuinely supportive, what needs to be personalised, and how to talk about health without placing unrealistic pressure back onto patients.Amy also shares more about the PAVING the Path to Wellness for breast cancer survivors. This program is designed to support breast cancer survivors and those navigating menopause with practical, evidence-based tools.I promise you will walk away loving Amy just as much as I do! Listen and be inspired!Resources & links mentioned in this episode:PAVING a Woman's Path Through Menopause and Beyond

Topic: Why More Cancer Is Being Diagnosed in Younger AdultsIntro: We're seeing more cancers diagnosed in adults under 50—why is this happening?Dr. Brittany Case, medical oncologist at Southern Cancer Center, is here to discuss what we know, what we don't know, and how care is changing.

We are in Week 3 of our 4-part series on Cancer, the #2 killer in America.   Early diagnostics have helped reduce the death rate from Cancer.  In this episode, you'll discover:—Why Dr. Prather says that diagnostics are even more important in the Structure-Function Health Care than in Disease Care.—The story of the oncologists who are surprised at how early Holistic Integration is able to detect certain types of Cancer that are usually not found until they are far more developed. —How Dr. Prather has over 600 hours of studying bloodwork, while the typical Medical Doctor has 15 hours of study in their education.—Why Liver Enzymes are so important in Cancer Diagnostics.  And how Dr. Prather says keeping those levels where they should be actually helps patients to be able to complete their Chemotherapy and Radiation treatments. —The reason Dr. Prather does not recommend Coffee Enemas and instead offers his patients a safer and more gentle form of detoxification. —The astonishingly low percentage of patients who first come into Holistic Integration who have the right lab test values for their Liver and their Immune system.—Why tumor markers are important in Cancer diagnostics and in evaluating care.  And why Dr. Prather tests for these more often than most Oncologists do. —The importance of Hair Analysis to determine Heavy Metals in the body that can lead to Cancer.  And the worst toxin for Cancer, which was found in Agent Orange and passed onto the daughters of Vietnam Veterans who were exposed to it. —How 80% of the immune system is found in the gut, which is best tested through a stool kit.  And the stories of Cancer patients who were helped because of the toxins, parasites, and infections detected in their stool kit. —The Micronutrients blood test that Dr. Prather recommends to all of his Cancer patients, which can help both in the prevention of Cancer and increasing someone's odds of surviving it.http://www.TheVoiceOfHealthRadio.com*Receive exclusive bonus content as a member of our Voice Of Health Patreon Community:https://www.patreon.com/cw/VoiceofHealthPodcast

In this unique episode of DairyVoice, host Tim Abbott of Showbox Sires talks with Dr. Dennis Sanders, his Oncologist for the past 25 years, about the many aspects of this disease. They discuss Tim's attitude and desire to battle the disease, the importance of gaining education and science that has developed over the past couple decades. They give advice on what a person should do when they or someone they know is diagnosed with cancer and what the future of treatment may look like.

“When Jesus heard it, He said to them, ‘Those who are well have no need of a physician, but those who are sick. I did not come to call the righteous, but sinners, to repentance.’” (Mark 2:17 NKJV) Jesus interacted with a remarkably diverse group of people during His public ministry. The Gospels record His encounters with Pharisees, tax collectors, Roman officials, fishermen, a Samaritan woman, and a host of others. One of the extraordinary things about these encounters is the personalized attention He gave each person, whether He was offering encouragement, rebuke, or healing. He recognized that every man, every woman, and every child is different. And though they have many of the same problems and the same basic needs, He realized that there were unique things about them that required individual ministry. He saw people for exactly who they were. He understood exactly what they needed. And He provided it. It’s no wonder people refer to Him as the Great Physician. Jesus Himself said, “Those who are well have no need of a physician, but those who are sick. I did not come to call the righteous, but sinners, to repentance” (Mark 2:17 NKJV). Like a physician, Jesus usually saw people at their worst. I’ve always thought that one of the hardest things about being a doctor is that you only see people when they’re sick or in need of medical assistance. Most physicians don’t get a lot of patients stopping by their office to say, “Hey, Doc, I’m feeling great! I just wanted to let you know. Want to go to lunch?” You don’t usually call your doctor when you’re feeling good. You call when you’re feeling sick. And your doctor will have you come in, examine you, and apply the necessary treatment to the area of need. Doctors, of course, are limited in their areas of expertise. Cardiologists specialize in heart health. Dermatologists specialize in matters of the skin. Gastroenterologists specialize in digestive system health. Hematologists specialize in blood disorders. Oncologists specialize in cancer treatment. The list goes on and on. Jesus, on the other hand, can treat the whole person. He caused the blind to see, the deaf to hear, the disabled to walk, and the dead to live. He removed the spiritual torment of the demon-possessed. He eased the emotional struggles of the frightened and grieving. He didn’t just improve people’s quality of life; He gave them a life they never knew was possible. That’s what He meant when He said, “I have come that they may have life, and that they may have it more abundantly” (John 10:10 NKJV). Jesus still provides personalized care for His people. He knows what you need. In fact, He knows better than you do what you need. And He can and will provide it. Reach out to Him. Open yourself to His loving ministry. Let Him guide you into the life He has planned for you. Enjoy all the benefits of having a personal Physician. Reflection question: How has Jesus impacted your life in a personal way? Discuss Today's Devo in Harvest Discipleship! — The audio production of the podcast "Greg Laurie: Daily Devotions" utilizes Generative AI technology. This allows us to deliver consistent, high-quality content while preserving Harvest's mission to "know God and make Him known." All devotional content is written and owned by Pastor Greg Laurie. Listen to the Greg Laurie Podcast Become a Harvest PartnerSupport the show: https://harvest.org/supportSee omnystudio.com/listener for privacy information.

Cervical Cancer Awareness Month with Dr. Ryan Kahn, gynecologic oncologist at Baptist Health Miami Cancer InstituteSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

Dr. Sue Hwang, author of, From Both Sides of the Curtain: Lessons and Reflections from an Oncologist's Breast Cancer Journey discusses the complex, frequently changing emotional landscape that every cancer patient faces.

A cancer diagnosis can feel overwhelming - but patients are not powerless. In this episode, Dr. Nainesh Parikh of Moffitt Cancer Center explains how patients and families can better advocate for themselves, navigate complex healthcare systems, and get connected to the right care at the right time.

New year, new interest rates? It's a strong maybe. That isn't the most helpful answer, but if you are close to closing on a new house, should you wait to see if they drop or lock in now? Nate Reineke and Chelsea Jones discuss some factors to consider when deciding whether to wait or not. We also look at how a change might already be factored into the rate you're getting. We also answer your colleagues' questions. A Psychiatrist in Maine says, “My 13-year-old just received a couple hundred bucks at Christmas. He is very interested in investing that money. He doesn't have any earned income. Is it best to open a UTMA in his name, a 529, or a Roth IRA?” A Double doctor family in Hawaii asks, “My 18-year-old son just committed to a paid internship for this coming summer and will make enough money to fully fund a Roth IRA. What is the best way to set this up?” An Oncologist in Oklahoma is wondering, “I looked at our last paycheque for the year 2025. Based on my calculations, it's likely that we will not meet the safe harbor rules for 2025. I am not sure how this happened, as we are both W2 employees. I know that we will have to pay some penalties, but should I hire a CPA for taxes this year? Generally, I do the taxes myself, but I am not sure if TurboTax can run this analysis.” Are you ready to turn worries about taxes and investing into all the money you need for college and retirement? It's time to make a plan and get on track. To find out if we're a match visit physicianfamily.com and click get started or, you can ask a question of your own by emailing podcast@physicianfamily.com. See marketing disclosures at physicianfamily.com/disclosures

What if the biggest obstacle to making good decisions about your health isn't a lack of information, but a nervous system in overdrive?When you're hit with a cancer diagnosis, your body goes into shock. Your mind starts racing with worst-case scenarios, and suddenly you're expected to make life-altering decisions about treatment while your system is anything but calm. Host Dr. Katie Deming sits down with Dr. Manuela Kogon, an integrative internist specializing in psycho-oncology, to explore why understanding your activated nervous system might be more important than any medical test when you're navigating cancer.Dr. Kogon explains why the word "should" is actually a red flag that your nervous system needs attention, and shares practical tools you can use right now to calm your body so your mind can make clearer choices. Chapters:04:42 - When the Diagnosis Hijacks Your Mind07:18 - Why Shock Destroys Clear Decision Making13:12 - Calm the Body Before You Choose Anything16:08 - The Should Trap That Worsens Healing18:47 - Control, Fear, and False Certainty22:31 - Quality vs Quantity of Life Choices29:22 - Choosing the Right Medical Team32:58 - When Loved Ones Make It Harder37:41 - Protecting Your Energy While HealingDr. Katie and Dr. Kogon explore the messy reality of competing needs, like choosing between quantity and quality of life, or dealing with loved ones who want you to make different treatment decisions. If you've ever felt paralyzed by medical decisions or wondered why your brain won't stop spinning worst-case scenarios, this conversation offers a completely different approach. Press play and learn how to make decisions from a place of calm instead of chaos.Connect with guest: https://www.whencancervisits.com/Access the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieDownload the FREE Healing Tools Guide: https://bit.ly/drkatie-giftguide MORE FROM KATIE DEMING M.D. Work with Dr. Katie: www.katiedeming.com 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Email: INFO@KATIEDEMING.COM Please Support the Show Share this episode with friends & family Give a Review on Spotify Give a Review on Apple Podcast Watch on Youtube: https://youtube.com/playlist?list=PL5LplU70TE9i01tW_7Tozi8b6X6rGBKA2&si=ZXLy5PjM7daD6AV5 DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not ...

Cervical cancer is one of the most preventable cancers, and when caught early, it's often highly curable. In fact, reports say Australia is on track to eliminate cervical cancer by 2035. However, many women still have unanswered questions about symptoms, screening and what a diagnosis really means. In this Baptist HealthTalk episode, host Johanna Gomez sits down with Dr. Ryan Kahn, a gynecologic oncologist with Baptist Health Cancer Care, to answer the most searched questions women have about cervical cancer. They cover why early stages are often symptom-free, the warning signs to watch for, how survival rates change by stage and what treatment can look like (surgery, chemo, radiation and newer targeted therapies). Dr. Kahn also clears up common misconceptions about HPV, the HPV vaccine and how often you actually need a Pap/HPV test. Listen now for clear, practical guidance to help you protect your health.If you're due for screening, or noticing changes, this episode helps you know what to do next.Host:Johanna GomezAward-Winning Host & JournalistGuest:Ryan Kahn, M.D. Gynecologic OncologistBaptist Health Cancer Care

Near-Death Experience Expert Dr. Jeffrey Long.  This Past Weekend w/ Theo Von. ACU Saturday Series.  Watch this video at- https://youtu.be/RfOGrMfcMPg?si=TO91iinJ8GHL59J6 Theo Von 4.4M subscribers 2,715,431 views Jan 23, 2024 This Past Weekend w/ Theo Von Dr. Jeffrey Long is a physician, author and researcher of near-death experiences. His book “Evidence of the Afterlife: The Science of Near-Death Experiences” is a New York Times Best-Seller that compiles research from more than 1,600 cases and interviews. Outside of his research he is a practicing Oncologist in Kentucky. Dr. Jeffrey Long joins Theo to talk about the phenomena of near-death experiences, what's really going on in our minds when we come close to the end, what people claim to see in their visions, why he believes there's an afterlife based on his research, and what we can learn from these experiences to get the most out of life. Dr. Jeffrey Long's book “Evidence of the Afterlife”: https://amzn.to/3OaVZHO Near-Death Experience Research Foundation: https://nderf.org/ ------------------------------------------------ Tour Dates! https://theovon.com/tour New Merch: https://www.theovonstore.com   --------------------------------------------------------------------  Check out our ACU Patreon page: https://www.patreon.com/ACUPodcast   HELP ACU SPREAD THE WORD!  Please go to Apple Podcasts and give ACU a 5 star rating. Apple canceled us and now we are clawing our way back to the top. Don't let the Leftist win. Do it now! Thanks. Also Rate us on any platform you follow us on. It helps a lot. Forward this show to friends. Ways to subscribe to the American Conservative University Podcast Click here to subscribe via Apple Podcasts Click here to subscribe via RSS You can also subscribe via Stitcher FM Player Podcast Addict Tune-in Podcasts Pandora Look us up on Amazon Prime …And Many Other Podcast Aggregators and sites ACU on Twitter- https://twitter.com/AmerConU . Warning- Explicit and Violent video content.   Please help ACU by submitting your Show ideas. Email us at americanconservativeuniversity@americanconservativeuniversity.com   Endorsed Charities -------------------------------------------------------- Pre-Born! Saving babies and Souls. https://preborn.org/ OUR MISSION To glorify Jesus Christ by leading and equipping pregnancy clinics to save more babies and souls. WHAT WE DO Pre-Born! partners with life-affirming pregnancy clinics all across the nation. We are designed to strategically impact the abortion industry through the following initiatives:… -------------------------------------------------------- Help CSI Stamp Out Slavery In Sudan Join us in our effort to free over 350 slaves. Listeners to the Eric Metaxas Show will remember our annual effort to free Christians who have been enslaved for simply acknowledging Jesus Christ as their Savior. As we celebrate the birth of Christ this Christmas, join us in giving new life to brothers and sisters in Sudan who have enslaved as a result of their faith. https://csi-usa.org/metaxas   https://csi-usa.org/slavery/   Typical Aid for the Enslaved A ration of sorghum, a local nutrient-rich staple food A dairy goat A “Sack of Hope,” a survival kit containing essential items such as tarp for shelter, a cooking pan, a water canister, a mosquito net, a blanket, a handheld sickle, and fishing hooks. Release celebrations include prayer and gathering for a meal, and medical care for those in need. The CSI team provides comfort, encouragement, and a shoulder to lean on while they tell their stories and begin their new lives. Thank you for your compassion  Giving the Gift of Freedom and Hope to the Enslaved South Sudanese -------------------------------------------------------- Food For the Poor https://foodforthepoor.org/ Help us serve the poorest of the poor Food For The Poor began in 1982 in Jamaica. Today, our interdenominational Christian ministry serves the poor in primarily 17 countries throughout the Caribbean and Latin America. Thanks to our faithful donors, we are able to provide food, housing, healthcare, education, fresh water, emergency relief, micro-enterprise solutions and much more. We are proud to have fed millions of people and provided more than 15.7 billion dollars in aid. Our faith inspires us to be an organization built on compassion, and motivated by love. Our mission is to bring relief to the poorest of the poor in the countries where we serve. We strive to reflect God's unconditional love. It's a sacrificial love that embraces all people regardless of race or religion. We believe that we can show His love by serving the “least of these” on this earth as Christ challenged us to do in Matthew 25. We pray that by God's grace, and with your support, we can continue to bring relief to the suffering and hope to the hopeless.   Report on Food For the Poor by Charity Navigator https://www.charitynavigator.org/ein/592174510   -------------------------------------------------------- Disclaimer from ACU. We try to bring to our students and alumni the World's best Conservative thinkers. All views expressed belong solely to the author and not necessarily to ACU. In all issues and relations, we hope to follow the admonitions of Jesus Christ. While striving to expose, warn and contend with evil, we extend the love of God to all of his children. ---------------------------------------------------------------------------

The holiday season brings many fun traditions, like going to see the lights, opening Advent calendars, baking, or shopping for the perfect gift. Since the holidays also signal the end of the year, it can be a time to think about taxes, too. Nate Reineke and Chelsea Jones break down some of the tax breaks doctors like you can try to catch at the last second, like maxing out contributions. We also look at some tax breaks that take a bit more planning, like charitable donations, that you could plan for in 2026. We also answer your colleagues' questions. An Anesthesiologist in Iowa says, “I want to help my son with a home purchase - what is the best way for me to do this?” An Oncologist in Colorado asks, “Do you think a really early retirement is worth pursuing?” A Family Medicine Doc in Texas says, “I've heard about this opportunity from a few colleagues to buy into this cash flow business (storage units). The projected return seems really appealing (20-30% over 3 years). What do you think?” Merry Christmas and Happy Holidays! Are you ready to turn worries about taxes and investing into all the money you need for college and retirement? It's time to make a plan and get on track. To find out if we're a match visit physicianfamily.com and click get started or, you can ask a question of your own by emailing podcast@physicianfamily.com. See marketing disclosures at physicianfamily.com/disclosures

This episode of the collaborative podcast between Oncology on the Go and the American Psychosocial Oncology Society (APOS), hosted by Daniel C. McFarland, DO, features Michelle B. Riba, MD, and focuses on integrating psychosocial care into oncology for clinicians. The discussion emphasizes that psychosocial issues profoundly impact both quality of life and cancer-related outcomes, making their assessment an integral part of care, not merely ancillary. The distress thermometer was developed by the NCCN in the late 1990s as a 0-to-10 scale, dubbed the "fifth vital sign". The term "distress" was chosen over psychiatric labels to capture the wide array of patient concerns, including pain, fatigue, sleep, spiritual, practical, and family issues. Distress screening is now mandated at regular appointments in all cancer centers in the US. Clinicians are encouraged to screen for more specific issues like depression (linked to poor adherence and survival), anxiety (which can impede treatment adherence), and substance use. Oncologists are the doctors most able to consider a patient's totality of symptoms, and their role is integral to supporting psychosocial referrals. To address the practical delivery of care, the collaborative care model is being advocated as a public health, population-based approach. Key components include: Use of a standardized screening tool. Management by a dedicated care manager. Weekly consultation between the care manager and a consultant psychiatrist for triage and treatment advice. The model allows oncologists to bill for care and learn more about these issues while ensuring patients receive evidence-based treatments. The clinicians concluded that fundamentally, mental health needs to be aligned alongside cancer care. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being the psycho-oncology editorial advisory board member for the journal ONCOLOGY. Riba is director of the PsychOncology Program, a clinical professor, and the associate chair for Integrated Medical and Psychiatric Services in the Department of Psychiatry at the University of Michigan Rogel Cancer Center, and psycho-oncology editorial advisory board member for the journal ONCOLOGY.

In this powerful episode, Fitz Koehler sits down with Dr. William L. Slayton—veteran pediatric oncologist and author—for a vital conversation about fighting childhood cancer and pushing hope forward. They cover real progress in pediatric cancer care, breakthroughs in immunotherapy, and what truly helps families endure treatment—movement, nutrition, mindset, and meaning. Dr. Slayton also shares the heart behind his book, Stunt Mole, and why his mission to help families is far from over. Thanks for keeping The Fitzness Show in the top 3% of all podcasts worldwide. Please subscribe, share, and leave a review.  Order signed copies of You. Supercharged! The Healthy Cancer Comeback Series books at Fitzness.com are on sale now! Follow Dr. Slayton's substack. Join the Hottie Body Fitzness Challenge group on Facebook!  

She was an oncologist responsible for 150 patients a night until a burnout-induced cardiac arrest stopped her heart and forced her to confront the toxic reality of the medical system. In this episode, Hannah Medic exposes the "embarrassing" truth about hospital pay, the identity crisis of leaving medicine, and why she refused to remain a cog in the machine. Watch to learn the exact holistic protocols and nervous system regulation tools she used to reverse her "incurable" autoimmune disease and how you can activate your own inner healer.-MY BOOK IS NOW OUT AND AVAILABLE RIGHT NOW:⁠⁠⁠⁠⁠⁠⁠⁠https://axelschura.com/maybe/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-HANNAH MEDIC:https://www.instagram.com/hannahmedic.official/ (English Instagram)https://www.hannahmedic.com/ (German Website)https://www.instagram.com/hannah.medic/ (German Instagram)-BOOK YOUR CALL NOW:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://axelschura.com/the-evergreen-blueprint/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-FREE LIVE WEBINAR FOR 10,000$ MONTHS AND DAYS:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://axelschura.com/live-webinar/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-MY WEBSITE:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://axelschura.com/⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-COACHING AND COMMUNITY:× 30 days FREE membership - change your life with my visualisation and meditation practices (new customers only):⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://axelschura.com/membership/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠× Free Webinar on Evergreen Products:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://event.webinarjam.com/register/6/yxqywig⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠× Free Strategy Session for Influencers, Agencies, Coaches, and Nutritionists:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://calendly.com/axelschurawlow/evergreen-blueprint⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠-SOCIALS:× Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/axelschura⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠× You can find me and my content on all social media platforms, just follow this Linktree: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/axelschura⁠⁠⁠⁠⁠⁠⁠⁠

Thank you for listening to the Stories That Heal Podcast. Please enjoy our Holiday Replays while we take some time to enjoy the holidays! __________ Dr. Mutti is a registered naturopathic doctor and a board-certified naturopathic oncologist. Her primary interest and strength is in providing compassionate care through close patient-physician relationships in a collaborative environment. As a Fellow of the American Board of Naturopathic Oncology, Dr. Mutti applies the art and science of naturopathic medicine to the field of cancer care and treatment, providing alternative and complementary medicine to patients living with cancer. American Association of Naturopathic Physicians - https://naturopathic.org Halsa Naturopathic - http://www.halsanaturopathic.com Instagram - https://www.instagram.com/halsanaturopathic/ FaceBook - https://www.facebook.com/halsanaturopathic/ __________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here.  To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. To learn more about Radical Remission health coaching with Liz or Karla, Click Here Follow us on Social Media: Facebook  Instagram YouTube _______________

There are concerns our health system isn't keeping pace with our accelerating cancer rates. The Cancer Control Agency's latest State of Cancer Report has found more New Zealanders are being diagnosed with cancer, but they're surviving cancer for longer. It's projecting diagnoses will increase by 50% over the next two decades. Otago University Medical Oncologist Dr Chris Jackson told Heather du Plessis-Allan this means fewer people getting scans, surgeries, and procedures. He says funding is increasing, but outcomes aren't improving at the same rate. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Oncologist and health care executive Yousuf Zafar discusses his article, "When cancer costs too much: Why financial toxicity deserves a place in clinical conversations." Yousuf explains the concept of "financial toxicity," a severe burden caused by both direct medical bills and indirect costs (like time off work or child care) associated with cancer treatment. He reveals the sobering statistic that over forty percent of patients deplete their savings within two years, but emphasizes that this distress is more than just a financial problem: it directly compromises treatment adherence, forcing some to skip appointments or forgo prescriptions. Yousuf highlights the critical lack of cost transparency in oncology and makes the case for why clinicians must proactively screen for financial strain just as they would for physical side effects. Discover why these difficult conversations about the cost of cancer are essential for improving patient outcomes and quality of life. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Dr. Monty Pal and Dr. Jason Westin discuss the federal funding climate for cancer research and the persistent problem of drug shortages, two of the major concerns facing the oncology community in 2026. TRANSCRIPT Dr. Monty Pal: Hello and welcome to the ASCO Daily News Podcast. I am your host, Dr. Monty Pal. I am a medical oncologist and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. There are always multiple challenges facing oncologists, and today, we discuss two of them that really stand out for 2026: threats to federal funding for cancer research and the persistent problem of drug shortages. I am thrilled to welcome Dr. Jason Westin, who believes that one way to meet these challenges is to get oncologists more involved in advocacy, and he will share some strategies to help us meet this moment in oncology. Dr. Westin is a professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, but he actually wears a lot of hats within ASCO. He is a member of the Board of Directors and has also previously served as chair of ASCO's Government Relations Committee. And he is also one of the inaugural members of ASCO's Political Action Committee, or PAC. He has testified before Congress about drug shortages and many other issues. Dr. Westin, I am really excited to have you on the podcast today and dive into some of these elements that will really impact our community in 2026. Thanks so much for joining us today. Dr. Jason Westin: Thank you for having me. Dr. Monty Pal: You've had such a range of experience. I already alluded to you testifying before Congress. You've actually run for office before. You wear so many different hats. I'm used to checking my PubMed every other day and seeing a new paper out from you and your group, and you publish in the New England Journal [of Medicine] on practice-setting standards and the diseases that you treat. But you've also done all this work in the domain of advocacy. I can't imagine that balancing that is easy. What has sort of motivated you on the advocacy front? Dr. Jason Westin: Advocacy to me is another way to apply our skills and help more people than just those that you're sitting across from at the time. Clinical research, of course, is a tool to try and take what we know and apply it more broadly to people that you'll never meet. And advocacy, I think, can do the same thing, where you can have a conversation with a lawmaker, you can advocate for a position, and that hopefully will help thousands or maybe even more people down the road who you'd never get to directly interact with. And so, I think it's a force multiplier in the same way that research can be. And so, I think advocacy is a wonderful part of how doctors care for our patients. And it's something that is often difficult to know where to start, but once people get into advocacy, they can see that the power, the rewarding nature of it is attractive, and most people, once they get going, continue with that through the rest of their career. Dr. Monty Pal: So, I'll ask you to expand on that a little bit. We have a lot of our younger ASCO members listening to this podcast, folks that are just starting out their careers in clinical practice or academia. Where does that journey begin? How do you get to the point that you're testifying in front of Congress and taking on these bigger sort of stances for the oncology community? Dr. Jason Westin: Yeah, with anything in medicine and in our careers, you have to start somewhere. And often you start with baby steps before you get in front of a panel of senators or other high-profile engagement opportunities. But often the first setting for junior colleagues to be engaged is doing things – we call them "Hill Days" – but basically being involved in kind of low-stakes meetings where you're with a group of peers, some of whom have done this multiple times before, and can get engaged talking to members of representatives' offices, and doing so in a way where it's a natural conversation that you're telling a story about a patient in your clinic, or that you're telling a personal experience from a policy that impacted your ability to deliver optimal care. It sounds stressful, but once you're doing it, it's not stressful. It's actually kind of fun. And it's a way that you can get comfort and skill with a group of peers who are there and able to help you. And ASCO has a number of ways to do that, both at the federal level, there's the Hill Day where we each April have several hundred ASCO members travel to Capitol Hill. There's also state engagement that can be done, so-called visiting at home, when representatives from the U.S. Congress or from state legislators are back in district. You can meet with your own representatives on behalf of yourself, on behalf of your organization, and advocate for policies in a way that can be beneficial to your patients. But those initial meetings that are in the office often they're low stakes because you could be meeting not with the representative but with their staff. And that staff sometimes is as young or even younger than our junior colleagues. These sometimes can be people in their 20s, but they're often extremely knowledgeable, extremely approachable, and are used to dealing with people who are new to advocacy. But they actually help make decisions within the office. So it's not a waste of time. It's actually a super useful way to engage. So, it's that first step of anything in life. The activation energy is always high to do something new. But I'd encourage people who are listening to this podcast already having some level of interest about it to explore ways that they could engage more. Dr. Monty Pal: You know, I have to tell you, I'm going to riff on what you just said for a second. ASCO couldn't make it any easier, I think, for folks to participate and get involved. So, if you're listening to this and scratching your head and thinking, "Well, where do I begin? How do I actually sign on for that meeting with a local representative?" Go to the ASCO ACT Network website. And I'll actually talk to our producer, Geraldine, to make sure we've got a link to that somewhere associated with this podcast after it's published, Jason, but I actually keep that on my browser and it's super easy. I check in there every now and then and see if there's any new policy or legislation that ASCO, you know, is sort of taking a stance on, and it gives me some fodder for conversation with my local representatives too. I mean, it's just an awesome, awesome vehicle. I'm going to segue right from there right to the issues. So, you and I are both at academic centers. You know, I think this is something that really pervades academia and enters into implications for general clinical practice. There's been this, you know, massive sort of proposal for decreased funding to the NCI and to the NIH and so forth. Tell us what ASCO is doing in that regard, and tell us perhaps how our community can help. Dr. Jason Westin: We live in interesting times, and I think that may be an understatement x 100. But obviously investments in research are things that when you're at an academic center, you see and feel that as part of your daily life. Members of Congress need to be reminded of that because there's a lot of other competing interests out there besides investing in the future through research. And being an elected representative is a hard job. That is something where you have to make difficult choices to support this, and that may mean not supporting that. And there's lots of good things where our tax dollars could be spent. And so, I'm sympathetic to the idea that there's not unlimited resources. However, ASCO has done an excellent job, and ASCO members have led the charge on this, of stating what research does, what is the benefit of research, and therefore why should this matter to elected representatives, to their staff, and to those people that they're elected to serve. And ASCO has led with a targeted campaign to basically have that message be conveyed at every opportunity to elected representatives. And each year on Hill Day, one of the asks that we have is to continue to support research: the NCI, NIH, ARPA-H, these are things that are always in the asks to make sure that there's appropriate funding. But effectively playing offense by saying, "It's not just a number on a sheet of paper, this is what it means to patients. This is what it means to potentially your loved ones in the future if you are in the opposite situation where you're not on the legislative side, but you're in the office receiving a diagnosis or receiving a difficult piece of news." We only have the tools we have now because of research, and each breakthrough has been years in the making and countless hours spent funded through the engine of innovation: clinical research and translational research. And so ASCO continues to beat that drum. You mentioned earlier the ACT Network. Just to bring that back again is a very useful, very easy tool to communicate to your elected representatives. When you sign up on the ASCO ACT website, you get emails periodically, not too much, but periodically get emails of, "This is a way you can engage with your lawmakers to speak up for this." And as you said, Monty, they make it as easy as possible. You click the button, you type in your address so that it figures out who your elected representatives are, and then it will send a letter on your behalf after like five clicks to say, "I want you to support research. I want you to vote for this particular thing which is of interest to ASCO and by definition to members of ASCO." And so the ACT Network is a way that people listening can engage without having to spend hours and significant time, but just a few clicks can send that letter to a representative in Congress. And the question could be: does that matter? Does contacting your senator or your elected representative do anything? If all they're hearing is somebody else making a different argument and they're hearing over and over again from people that want investments in AI or investments in something else besides cancer research, whatever it is, they may think that there's a ground shift that people want dollars to be spent over here as opposed to at the NIH or NCI or in federally funded research. It is important to continue to express the need for federal funding for our research. And so, it really is important for folks to engage. Dr. Monty Pal: 100%. One of the things that I think is not often obvious to a lot of our listeners is where the support for clinical trials comes from. You know, you've obviously run the whole gamut of studies as have I. You know, we have our pharmaceutical company-sponsored studies, which are in a particular bucket. But I would say that there's a very important and critical subset of studies that are actually government funded, right? NCI-funded clinical trials. If you don't mind, just explain to our audience the critical nature of the work that's being done in those types of studies and if you can, maybe compare and contrast the studies that are done in that bucket versus perhaps the pharmaceutical bucket. Dr. Jason Westin: Both are critical, and we're privileged that we have pharma studies that are sponsored and federally funded clinical research. And I think that part of a healthy ecosystem for us to develop new breakthroughs has a need for both. The pharma sponsored studies are done through the lens of trying to get an approval for an agent that's of interest so that the pharma company can then turn around and use that outside of a clinical trial after an FDA approval. And so those studies are often done through the lens of getting over the finish line by showing some superiority over an existing treatment or in a new patient population. But they're done through that lens of kind of the broadest population and sometimes relatively narrow endpoints, but to get the approval so that then the drug can be widely utilized. Clinical trials done through cooperative groups are sometimes done to try and optimize that or to try and look at comparative things that may not be as attractive to pharma studies, not necessarily going for that initial approval, but the fine tuning or the looking at health outcomes or looking at ensuring that we do studies in representative populations that may not be as well identified on the pharma sponsored trials, but basically filling out the gaps in the knowledge that we didn't gain from the initial phase 3 trial that led to the approval. And so both are critical. But if we only do pharma sponsored trials, if we don't fund federally supported research and that dries up, the fear I have, and many others have, is that we're going to be lacking a lot of knowledge about the best ways to use these great new therapies, these new immune therapies, or in my team, we do a lot of clinical trials on CAR T-cell therapies. If we don't have federally funded research to do the important clinical studies, we'll be in the dark about the best ways to use these drugs, and that's going to be a terrible shame. And so we really do need to continue to support federal research. Dr. Monty Pal: Yeah, there are no softball questions on this podcast, but I think everybody would be hard pressed to think that you and I would come on here and say, "Well, no, we don't need as much money for clinical trials and NCI funding" and so forth. But I think a really challenging issue to tackle, and this is something we thought to ask you ahead of the podcast, is what to do about the general climate of, you know, whether it's academic research or clinical practice here that seems to be getting some of our colleagues thinking about moving elsewhere. I've actually talked to a couple of folks who are picking up and moving to Europe for a variety of considerations, other continents, frankly. The U.S. has always been a leader when it comes to oncology research and, one might argue, research in general. Some have the mindset these days that we're losing that footing a little bit. What's your perspective? Are you concerned about some of the trends that you're seeing? What does your crystal ball tell you? Dr. Jason Westin: I am highly concerned about this. I think as you said, the U.S. has been a leader for a long time, but it wasn't always. This is not something that's preordained that the world-leading clinical research and translational research will always be done in the United States. That is something that has been developed as an ecosystem, as an engine for innovation and for job development, new technology development, since World War II. That's something that through intentional investments in research was developed that the best and brightest around the world, if they could choose to go anywhere, you wanted them to come to work at universities and academic places within the United States. And I think, as you said, that's at risk if you begin to dry up the investment in research or if you begin to have less focus on being engaged in research in a way that is forward thinking, not just kind of maintaining what we do now or only looking at having private, for profit sponsored research. But if you don't have the investment in the basic science research and the translational research and the forward-thinking part of it, the fear is that we lose the advantage and that other countries will say, "Thank you very much," and be happy to invest in ways to their advantage. And I think as you mentioned, there are people that are beginning to look elsewhere. I don't think that it's likely that a significant population of researchers in the U.S. who are established and have careers and families – I don't think that we're going to see a mass exodus of folks. I think the real risk to me is that the younger, up-and-coming people in undergraduate or in graduate school or in medical school and are the future superstars, that they could either choose to go into a different field, so they decide not to go into what could be the latest breakthroughs for cancer patients but could be doing something in AI or something in a different field that could be attractive to them because of less uncertainty about funding streams, or they could take that job offer if it's in a different country. And I think that's the concern is it may not be a 2026 problem, but it could be a 2036 or a 2046 problem that we reap what we sow if we don't invest in the future. Dr. Monty Pal: Indeed, indeed. You know, I've had the pleasure of reviewing abstracts for some of our big international meetings, as I'm sure you've done in the past too. I see this trend where, as before, we would see the preponderance of large phase 3 clinical trials and practice setting studies being done here in the U.S., I'm seeing this emergence of China, of other countries outside of the U.S. really taking lead on these things. And it certainly concerns me. If I had to sort of gauge this particular issue, it's at the top of my list in terms of what I'm concerned about. But I also wanted to ask you, Jason, in terms of the issues that are looming over oncology from an advocacy perspective, what else really sort of keeps you up at night? Dr. Jason Westin: I'm quite concerned about the drug shortages. I think that's something that is a surprisingly evergreen problem. This is something that is on its face illogical that we're talking about the greatest engine for research in the world being the United States and the investment that we've made in drug development and the breakthroughs that have happened for patients all around the world, many of them happen in the United States, and yet we don't necessarily have access to drugs from the 1970s or 1980s that are cheap, generic, sterile, injectable drugs. This is the cisplatins and the vincristines and the fludarabine type medications which are not the sexy ones that you see the ads in the magazine or on TV at night. These are the backbone drugs for many of our curative intent regimens for pediatrics and for heme malignancies and many solid tumors. And the fact that that's continuing to be an issue is, in my opinion, a failure to address the root causes, and those are going to require legislative solutions. The root causes here are basically a race to the bottom where the economics to invest in quality manufacturing really haven't been prioritized. And so it's a race to the cheapest price, which often means you undercut your competitor, and when you don't have the money to invest in good manufacturing processes, the factory breaks down, there's no alternative, you go into shortage. And this has been going on for a couple of decades, and I don't think there's an end in sight until we get a serious solution proposed by our elected officials. That is something that bothers me in the ways where we know what we should be doing for our patients, but if we don't have the drugs, we're left to be creative in ways we shouldn't have to do to figure out a plan B when we've got curative intent therapies. And I think that's a real shame.  There's obviously a lot of other things that are concerning related to oncology, but something that I have personally had experience with when I wanted to give a patient a CAR T-cell, and we don't have a supply of fludarabine, which is a trivial drug from decades ago in terms of the technology investments in genetically modified T-cells, to not then have access to a drug that should be pennies on the dollar and available at any time you want it is almost like the Air Force investing in building the latest stealth bomber, but then forgetting to get the jet fuel in a way that they can't use it because they don't have the tools that they need. And so I think that's something that we do need to have comprehensive solutions from our elected officials. Dr. Monty Pal: Brilliantly stated. I like that analogy a lot. Let's get into the weeds for a second. What would that proposal to Congress look like? What are we trying to put in front of them to help alleviate the drug shortages? Dr. Jason Westin: We could spend a couple hours, and I know podcasts usually are not set up to do that. And so I won't go through every part. I will direct you that there have been a couple of recent publications from ASCO specifically detailing solutions, and there was a recent white paper from the Senate Finance Committee that went through some legislative solutions being explored. So Dr. Gralow, ASCO CMO, and I recently had a publication in JCO OP detailing some solutions, more in that white paper from the Senate Finance. And then there's a working group actually going through ASCO's Health Policy Committee putting together a more detailed proposal that will be published probably around the end of 2026. Very briefly, what needs to happen is for government contracts for purchasing these drugs, there needs to be an outlay for quality, meaning that if you have a manufacturing facility that is able to deliver product on time, reliably, you get a bonus in terms of your contract. And that changes the model to prioritize the quality component of manufacturing. Without that, there's no reason to invest in maintaining your machine or upgrading the technology you have in your manufacturing plant. And so you have bottlenecks emerge because these drugs are cheap, and there's not a profit margin. So you get one factory that makes this key drug, and if that factory hasn't had an upgrade in their machines in 20 years, and that machine conks out and it takes 6 months to repair or replacement, that is an opportunity for that drug to go into shortage and causes a mad dash for big hospitals to purchase the drug that's available, leaving disparities to get amplified. It's a nightmare when those things happen, and they happen all the time. There are usually dozens, if not hundreds, of drugs in shortage at any given time. And this has been going on for decades. This is something that we do need large, system-wide fixes and that investment in quality, I think, will be a key part. Dr. Monty Pal: Yeah, brilliantly said. And I'll make sure that we actually include those articles on the tagline for this podcast as well. I'll talk to our producer about that as well.  I'm really glad you mentioned the time in your last comment there because I felt like we just started, but in fact, I think we're right at our close here, Jason, unfortunately. So, I could have gone on for a couple more hours with you. I really want to thank you for these absolutely terrific insights and thank you for all your advocacy on behalf of ASCO and oncologists at large. Dr. Jason Westin: Thank you so much for having me. I have enjoyed it. Dr. Monty Pal: Thanks a lot. And many thanks to our listeners too. You can find more information about ASCO's advocacy agenda and activities at asco.org. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks so much. ASCO Advocacy Resources: Get involved in ASCO's Advocacy efforts: ASCO Advocacy Toolkit Crisis of Cancer Drug Shortages: Understanding the Causes and Proposing Sustainable Solutions, JCO Oncology Practice Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Monty Pal   @montypal   Dr. Jason Westin @DrJasonWestin   Follow ASCO on social media:      @ASCO on X     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Jason Westin: Consulting or Advisory Role: Novartis, Kite/Gilead, Janssen Scientific Affairs, ADC Therapeutics, Bristol-Myers Squibb/Celgene/Juno, AstraZeneca, Genentech/Roche, Abbvie, MorphoSys/Incyte, Seattle Genetics, Abbvie, Chugai Pharma, Regeneron, Nurix, Genmab, Allogene Therapeutics, Lyell Immunopharma Research Funding: Janssen, Novartis, Bristol-Myers Squibb, AstraZeneca, MorphoSys/Incyte, Genentech/Roche, Allogene Therapeutics

In this episode of Parts and Labor, Angela Chaudhari, MD, hosts a panel of experts from Northwestern Medicine's Division of Gynecologic Oncology to explore the innovative role of robotic surgery in cancer care. The discussion highlights how robotic technology is improving outcomes for patients with gynecologic cancers through minimally invasive techniques, enhanced precision and interdisciplinary collaboration.The panel covers advancements in robotic systems, patient populations who benefit most from this approach, including those with high BMI, complex surgical histories, and fertility concerns, as well as the future of surgical innovation at Northwestern Medicine.This episode's panel of guests includes:• Emma L. Barber, MD, John and Ruth Brewer Professor of Gynecology and Cancer Research, Division Chief of Gynecologic Oncology and Director of Robotic Surgery.• Dario R. Roque, MD, Associate Professor of Gynecologic Oncology and Fellowship Program Director.• Jenna Z. Marcus, MD, Associate Professor of Gynecologic Oncology, Director of Robotic Simulation and Associate Fellowship Program Director.

 JR Richardson expressed overwhelming disbelief at his cancer-free diagnosis, stating he had been mentally prepared to die and was still recalibrating his mindset about surviving for his two children aged 15 and 17.Medical misdiagnoses occurred from 2018-2021 when JR's symptoms including pressure in his taint area were attributed to a fistula, fissure, and prostatitis rather than recognizing his PSA level of 21 as a cancer indicator.Healthcare providers failed to communicate the significance of JR's PSA level of 21, simply recommending a blood test without urgency, leading to a delayed diagnosis when his PSA reached 85.6 by the time of proper testing.Oncologist provided a grim prognosis of two to five years with palliative care options including abiraterone, steroids, and hormone blockers, offering no alternative treatment choices.JR declined conventional treatment initially, having been familiar with cannabis oil since Phoenix Tears and connected with Valerie Corral from WAMM, the first cannabis cooperative in the United States.Valerie Corral was identified as the pioneer who developed the 4:1 cannabis ratio and successfully sued the federal government after a farm raid, winning her case with Santa Cruz County support.Cannabis oil treatment began with JR taking a gram of oil he had made, but Corey Yelland advised switching to 4:1 ratio rectal administration for better effectiveness.PSA levels dropped dramatically from 85.6 to 29 within one month of starting 4:1 rectal cannabis treatment, and further decreased to 3.82 after receiving one hormone injection.Continued cannabis treatment brought PSA levels to normal range, with readings of 2.33, 1.82, and stabilizing around 1.72, demonstrating sustained improvement.Stanford Medical provided a second opinion contradicting the initial oncologist's palliative approach, recommending the Stampede Study protocol with pinpoint radiation on lymph nodes and two small spinal spots.Radiation treatment decision was made after consultation with a knowledgeable technician who explained advances in precision radiation technology, addressing JR's concerns about radiation damage based on his aunt's experience.Daily cannabis dosage consisted of at least one gram of CBG orally and two grams rectally with 10-20% lipid addition, plus additional oral THC, prioritizing survival over psychoactive effects.Valerie Corral's experience indicated that long-term cancer survivors in her practice had used both Western medicine and cannabis oil, influencing JR's decision to combine treatments.Recent scan results showed no metabolically active disease in previously affected areas including nodes and spine, confirming complete remission and validating the combined treatment approach. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What if cancer risk has far less to do with your weight than your insulin?Dr. Katie Deming sits down with Dr. Christy Kesslering, a fellow radiation oncologist who made the same unconventional leap out of Western medicine. Their conversation opens doors to understanding how metabolism influences cancer in ways most doctors never discuss with their patients.Dr. Kesslering reveals how her personal health struggles uncovered something most oncologists miss completely: insulin drives cancer growth far more than weight ever could. Chapters:05:32 - Emotional Roots of Cancer07:12 - Why She Left Radiation Oncology09:48 - Redefining Integrative vs Functional Medicine12:55 - The Power of Nutrient-Dense Real Food16:04 - The Most Revealing Cancer Biomarkers21:48 - Ketogenic Diet During Treatment26:35 - Steroids, Chemo, and Better Outcomes30:52 - Fasting vs Fasting Mimicking Diet36:22 - Radiation Protocols and Ketosis40:05 - Carnivore vs Carnivore-ish47:50 - Ketone Levels and Real-World HealingShe brings years of real clinical experience counseling patients on metabolic approaches right alongside their radiation treatment. You'll discover the specific blood markers that show what's truly happening beneath the surface and why your regular lab work probably isn't telling you the whole story.They break down exactly how to use fasting strategically around chemotherapy and radiation. Dr. Kesslering also tackles the truth about carnivore diets, hidden plant toxins, and why those trendy "fasting mimicking" packages might be doing more harm than good.You'll want to stay until the end because Dr. Kesslering reveals why chasing the "perfect" ketosis numbers might actually be sabotaging your healing, and what matters far more than any measurement you'll find in research studies.Listen and learn what two radiation oncologists discovered when they stopped treating symptoms and started addressing the metabolic terrain where cancer actually thrives.Connect with Dr. Christy Kesslering: Access the FREE Water Fasting Masterclass Now: https://www.katiedeming.com/the-healing-power-of-fasting/ Transform your hydration with the system that delivers filtered, mineralized, and structured water all in one. Spring Aqua System: https://springaqua.info/drkatieMORE FROM KATIE DEMING M.D. Work with Dr. Katie: www.katiedeming.com 6 Pillars of Healing Cancer Workshop Series - Click Here to Enroll Follow Dr. Katie Deming on Instagram: https://www.instagram.com/katiedemingmd/ Email: INFO@KATIEDEMING.COM Please Support the Show Share this episode with a friend or family member Give a Review on Spotify Give a Review on Apple Podcast Watch on Youtube: https://youtube.com/playlist?list=PL5LplU70TE9i01tW_7Tozi8b6X6rGBKA2&si=ZXLy5PjM7daD6AV5 DISCLAIMER: The Born to Heal Podcast is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.

On this episode, Dr. Debra A. Wong, Medical Oncologist at City of Hope and Medical Director at AccessHope, joins the podcast to discuss better supporting frontline oncologists in resource-limited settings, improving cancer care access, and the importance of not losing sight of the human element in care.

On this episode, Dr. Debra A. Wong, Medical Oncologist at City of Hope and Medical Director at AccessHope, joins the podcast to discuss better supporting frontline oncologists in resource-limited settings, improving cancer care access, and the importance of not losing sight of the human element in care.

On this episode, Dr. Debra A. Wong, Medical Oncologist at City of Hope and Medical Director at AccessHope, joins the podcast to discuss better supporting frontline oncologists in resource-limited settings, improving cancer care access, and the importance of not losing sight of the human element in care.

Lauren, a native of Madison, WI, graduated with a B.S. in Molecular Biology and Spanish from the University of Wisconsin–Madison. She then earned her M.D. at Stanford University, where she was awarded a Howard Hughes Medical Institute (HHMI) research scholarship to study osteosarcoma at the National Cancer Institute (NCI) in Washington, D.C. She completed her internship at Santa Clara Valley Medical Center in San Jose, CA, followed by a residency in radiation oncology at Memorial Sloan-Kettering Cancer Center in New York City. After residency, Lauren joined the faculty of the University of Wisconsin Carbone Cancer Center, where she focused on thoracic radiation oncology and helped develop a spine stereotactic radiation program. In 2014, she transitioned to The Permanente Medical Group, serving as a radiation oncologist at Kaiser Permanente in Northern California and later as regional lymphoma subspecialty lead until her departure in 2023. She then joined the University of Colorado Department of Radiation Oncology, where she served on the faculty until June 2025.Lauren is currently pursuing additional training in palliative care while continuing to provide locum tenens radiation oncology coverage across Colorado and California. She is passionate about delivering evidence-based, patient-centered care—a commitment that is deeply personal and influenced by her experiences watching both of her parents undergo cancer treatment.The desire to be closer to friends and family—and a shared love of the outdoors—brought Lauren and her family to Colorado. She resides in Morrison with her husband, Anthony, a native of England who runs a consulting practice specializing in cell and gene therapies. Together they enjoy the lively company of their two children, Anna and Charlie, along with an ever-growing menagerie of pets. As a family, they love hiking, gardening, sharing tea and biscuits, and catching up on sleep whenever possible.**********************************************************Judy Carlson is the CEO and Founder of the Judy Carlson Financial Group, where she helps couples create personalized, coordinated financial plans that support the life they want to live – now and in the future.As an Independent Fiduciary and Comprehensive Financial Planner, Judy specializes in retirement income and wealth decumulation strategies. She is a CPA, Investment Advisor Representative, licensed in life and health insurance, and certified in long-term care planning.Judy's mission is to help guide clients with clarity and care, building financial plans that focus on real planning built around real lives.Learn More: https://judycarlson.com/The Inspired Impact Podcasthttps://businessinnovatorsradio.com/the-inspired-impact-podcast/Source: https://businessinnovatorsradio.com/the-inspired-impact-podcast-with-judy-carlson-interview-with-lauren-shapiro-md-radiation-oncologist

How might the advent of IDH inhibitors impact the practice of radiation oncologists and their role within the wider multidisciplinary team? Credit available for this activity expires: 11/20/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/highlights-san-francisco-evolving-role-radiation-oncologist-2025a1000uyk?ecd=bdc_podcast_libsyn_mscpedu

GDP Script/ Top Stories for November 20th Publish Date: November 20th PRE-ROLL: SUGAR HILL ICE SKATING From the BG AD Group Studio Welcome to the Gwinnett Daily Post Podcast. Today is Thursday, November 20th and Happy birthday to Bobby Kennedy I’m Peyton Spurlock and here are your top stories presented by KIA Mall of Georgia. Lawmakers consider paring tax credits and exemptions to offset income tax cuts Piedmont Eastside and Piedmont Oncology welcome medical oncologist Sami Ali Gwinnett commissioners to issue bonds for Gas South Arena renovations Plus, Leah McGrath from Ingles Markets on rice All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe! Break 1: STRAND THEATRE STORY 1: Lawmakers consider paring tax credits and exemptions to offset income tax cuts  Georgia lawmakers are seriously considering wiping out the state income tax—$16 billion in revenue—and replacing it by slashing $30 billion in tax credits and exemptions. “It’s not if, it’s when,” said Sen. Blake Tillery, who’s leading the charge. He called it a move for “competitiveness.” Supporters like economist Arthur Laffer praised states like Tennessee for thriving without income taxes, calling it “really cool” not to file returns. But critics, like Sen. Nan Orrock, warned it could hit low-income families and retirees hardest, especially if sales taxes rise. The debate? Far from settled. STORY 2: Piedmont Eastside and Piedmont Oncology welcome medical oncologist Sami Ali  Piedmont Eastside Medical Center and Piedmont Oncology are thrilled to welcome Dr. Sami Ali to their team. Dr. Ali, a board-certified hematologist and oncologist, brings years of experience treating patients with lung cancer, colorectal cancer, blood disorders, and more. Before joining Piedmont, Dr. Ali spent eight years at The Oncology Institute in Los Angeles, where he provided personalized care, led treatment plans, and contributed to clinical research. “We’re excited to have him,” said Larry Ebert, Piedmont Eastside’s CEO. “His expertise will help us expand cancer care in Gwinnett County.” Dr. Ali is now accepting new patients. For appointments, visit Piedmont.org or call 678-639-3950. STORY 3: Gwinnett commissioners to issue bonds for Gas South Arena renovations   Gwinnett County commissioners took a big step Tuesday toward funding a major facelift for the 23-year-old Gas South Arena. The plan? Revenue bonds—up to $172 million worth—to cover renovations like new seating, upgraded security, better concessions, and even a shiny new parking deck. The total cost? Somewhere between $170 and $176 million. The county might chip in $40 million to ease the debt load, according to Financial Services Director Russell Royal. What’s changing? Think premium seating, revamped suites, modernized restrooms, grab-and-go food, and a high-tech security plaza. Oh, and the roof, HVAC, and electrical systems? All getting replaced. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info. We’ll be right back Break 2: 07.14.22 KIA MOG STORY 4: Georgia Gwinnett College celebrates International Education Week   Georgia Gwinnett College turned International Education Week into a colorful, culture-packed celebration that brought the world to campus. From Nov. 10, students and staff dove into 14 events—everything from global traditions to study-abroad opportunities. The highlight? A visit from Lithuania’s Consul General, DOH-vee-dahs Dovydas shpo-KOW-skas Špokauskas, who spoke on diplomacy and security, thanks to professor DOH-vee-leh Dovilė boo-DREE-teh Budryte. Korean culture stole the show at Seoul Connections, with K-Pop, snacks, and games filling the room. And the International Thanksgiving? A feast of global flavors, live music, and a cultural fashion show. The week wrapped with poetry, music, and a reminder: the world’s waiting—go explore it. STORY 5: Gwinnett waiving tax penalties for residents impacted by government shutdown Gwinnett County is throwing a lifeline to residents hit hard by the recent federal shutdown. On Tuesday, commissioners gave Tax Commissioner Denise Mitchell the green light to waive penalties and interest on late ad valorem taxes for those furloughed or who lost SNAP benefits during the chaos. “Georgia law lets me waive penalties for reasonable cause,” Mitchell explained. “And over the past few weeks, I’ve heard from residents struggling to pay their bills because of the shutdown.” This doesn’t erase the taxes—just the late fees. To qualify, folks need proof of furlough or lost benefits, and the waiver only covers bills due during or shortly after the shutdown. We’ll be right back. Break 3: THE SUGAR HILL HOLIDAY And now here is Leah McGrath from Ingles Markets on rice Break 4: BUFORD HOLIDAY FESTIVAL We’ll have closing comments after this Break 5: Ingles Markets 8 Signoff – Thanks again for hanging out with us on today’s Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network Show Sponsors: www.ingles-markets.com www.kiamallofga.com Strand Marietta – Earl and Rachel Smith Strand Theatre Ice Rink – Downtown Sugar Hill Holiday Celebration 2025 – City of Sugar Hill 2025 Buford Holiday Festival & Parade All-In-One Flyer News Podcast, Current Events, Top Headlines, Breaking News, Podcast News, Trending, Local News, Daily, News, Podcast, Interviews See omnystudio.com/listener for privacy information.

Melissa sits down with Dr. Laila Agrawal, a board-certified breast oncologist who leads a sexual health clinic dedicated to the breast cancer community. As part of the "Empowered Intimacy: Getting Your Sexy Back After Breast Cancer" series, they talk about how to restore sexual comfort, pleasure, and connection after a breast cancer diagnosis. Dr. Agrawal offers practical guidance on vibrators, lubricants, vaginal estrogen, and pelvic floor therapy, while clearing up common misconceptions and stressing the importance of open communication with both partners and providers. This episode focuses on both the emotional and physical sides of intimacy and teaches listeners how to regain desire, comfort, and confidence in their sexual health after a breast cancer diagnosis. Special thanks to Lilly and Novartis for supporting the Cancer Fashionista Foundation and making this series possible.

In this episode, Joe Moore sits down with Dr. Jason Konner, a longtime oncologist who recently left his full-time clinical role at Memorial Sloan Kettering to devote himself to the emerging intersection of cancer care and psychedelics. Dr Konner shares how, after more than two decades treating people, he hit a wall. The accumulated grief, constant exposure to death, and intensity of oncology left him deeply burned out, though he didn't have that language for it at the time. A chance moment in a yoga class, overhearing someone say "ayahuasca retreat" just before he was scheduled for hernia surgery, became the turning point. Within a week, he was in the jungle. That first week with ayahuasca, followed later by work with mushrooms, "absolutely transformed" his life. His fear of death lifted. The burnout he hadn't even recognized in himself was both revealed and relieved. When he returned to his practice, Konner describes feeling like he suddenly had a "superpower": he could stay present, connected, and compassionate with patients facing advanced disease without collapsing under the emotional weight. He and Joe explore what this third path looks like: not the classic binary between either hardening and distancing as self-protection, or staying open-hearted and getting shattered. Instead, psychedelics helped him hold deep relationship with patients and families while maintaining inner stability and meaning. This opened space for authentic conversations about spirituality, fear, grief, and what it means to live with (or die from) cancer. From there, Dr Konner zooms out to critique the broader oncology system: The lack of training and support for oncologists around their own emotional and existential load, How little space there is for relational work even though it's central to healing, Why many support groups and standard psychiatric approaches (like reflexively prescribing SSRIs) often miss the mark for people dealing with cancer, How caregivers, partners, family members, and others are deeply affected but rarely truly supported. Joe and Jason then dig into psychedelics and oncology as a frontier: easing existential distress in patients with terminal cancer, the neglected suffering of caregivers, the potential role of psychedelics in helping people relate differently to death, and what it might mean for ICU use, aggressive end-of-life interventions, and overall healthcare costs if more people could make decisions from a place of peace rather than terror. Dr Konner also shares a striking ovarian cancer case that hinted at powerful immune changes after shamanic work, and why he believes we need new research paradigms that can honor the integrity of retreat and ceremonial settings while still learning from them. Finally, he talks about his early-stage project, Psychedelic Oncology, and his hope that the first wave of change starts with clinicians themselves becoming more psychedelic-literate—and, where appropriate, doing their own inner work—so better options can eventually reach the people who need them most. Learn more - https://psychedeliconcology.com/

I feel honoured to share this third conversation with Jannine Gearon who I interviewed before in May and June this year. Jannine lives with cholangiocarcinoma (bile duct cancer) - a rare and aggressive cancer with very confronting statistics. In our previous two episodes, she bravely shared her journey, including her decision to explore voluntary assisted dying (VAD) as a way of reclaiming a sense of choice amidst pain and uncertainty. Today, there's a plot twist. A newly available targeted drug, found by her sister at what felt like the literal 11th hour, has begun changing the trajectory of her disease. Her latest scan and bloods show things are not progressing as expected - in the best possible way. As Jannine says, “the cancer is not behaving as it should,” and her oncologist is now cautiously optimistic. May this episode entangle in the quantum field with the exact people who are meant to hear it, and create beautiful ripples in your life and the lives of those you love.

Featuring an interview with Dr Aaron Lisberg, including the following topics: Prevention and Management of Adverse Events of Special Interest with Datopotamab Deruxtecan (Dato-DXd) (0:00) Rugo H et al. US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan. Support Care Cancer 2025;33(9):756. Abstract Lisberg A et al. Datopotamab deruxtecan-associated select adverse events: Clinical practices and institutional protocols on prophylaxis, monitoring, and management. Oncologist 2025;[Online ahead of print]. Abstract Meric-Bernstam F et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis. Oncologist 2025;30(3). Abstract Novel Strategies Combining Dato-DXd with Osimertinib (10:44) Lu S et al. TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC). ASCO 2025;Abstract TPS8647. Nadal E et al. TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib. ELCC 2025;Abstract 124TiP. Intracranial Activity Observed with TROP2-Targeting Antibody-Drug Conjugates (15:14) Felip E et al. Brain metastases and actionable genetic alterations with sacituzumab govitecan versus docetaxel in metastatic non-small cell lung cancer: Subgroups of the phase III EVOKE-01 trial. ELCC 2025;Abstract 13P. Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593. Pons-Tostivint E et al. Intracranial efficacy of datopotamab deruxtecan (Dato- DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01. WCLC 2025;Abstract OA10.01. CME information and select publications

What really causes cancer? Will we ever find a cure? And why does our mistrust of medicine and obsession with big pharma conspiracies have such a grip on the way we think about it? In this episode, Jonathan Van Ness sits down with oncologist Dr. Stacy Wentworth to explore the biggest questions surrounding cancer—what science can tell us, what it can't (yet), and how to reframe the way we talk about this disease. From cutting through fear and misinformation to finding space for hope and empowerment, this conversation offers clarity and compassion for anyone touched by cancer. Full Getting Better Video Episodes now available on YouTube.  Follow Dr. Stacy Wentworth on Instagram @drstacywentworth  Follow us on Instagram @gettingbetterwithjvn  Follow Jonathan on Instagram @jvn Follow Dr. Stacy's Substack here.  BIO: Dr. Wentworth is an award-winning physician, author, and cancer survivorship expert.  She has two decades of experience leading patient centered care teams in diverse settings – from NCI designated comprehensive cancer centers to rural hospitals. Her research has been featured at national conferences and published in peer-reviewed journals. Dr. Wentworth is the founder of the Cancer Culture Substack, where she explores how personal beliefs, history, and science influence our experience and attitude toward cancer. Senior Producer, Chris McClure Producer, Editor & Engineer is Nathanael McClure Production support from Anne Currie and Chad Hall Our theme music is also composed by Nathanael McClure. Check out the JVN Patreon for exclusive BTS content, extra interviews, and much much more - check it out here: www.patreon.com/jvn Curious about bringing your brand to life on the show? Email podcastadsales@sonymusic.com. Learn more about your ad choices. Visit podcastchoices.com/adchoices